Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.

Science translational medicine - 14 May 2014

Perova Tatiana, Grandal Ildiko, Nutter Lauryl M J, Papp Eniko, Matei Irina R, Beyene Joseph, Kowalski Paul E, Hitzler Johann K, Minden Mark D, Guidos Cynthia J, Danska Jayne S

Abstract excerpt

Intensified and central nervous system (CNS)-directed chemotherapy has improved outcomes for pediatric B cell acute lymphoblastic leukemia (B-ALL) but confers treatment-related morbidities. Moreover, many patients suffer relapses, underscoring the need to develop new molecular targeted B-ALL therapies. Using a mouse model, we show that leukemic B cells require pre-B cell receptor (pre-BCR)-independent spleen...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Morpholines

Share to Neoplasm Transplantation

Share to Niacinamide

Share to Oxazines

Share to Precursor Cells, B-Lymphoid

Share to Syk Kinase

Source

Identifiers

PMID: 24828076
DOI: 10.1126/scitranslmed.3008661

Genes

SYK
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.PMID 24828076Read ↗

Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomasSemantic proximity Read ↗

Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.Semantic proximity Read ↗

LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors.Semantic proximity Read ↗

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic targetSemantic proximity Read ↗

SYK is a critical regulator of FLT3 in acute myeloid leukemia.Semantic proximity Read ↗

SYK inhibition and response prediction in diffuse large B-cell lymphomaSemantic proximity Read ↗

Mouse xenograft modeling of human adult acute lymphoblastic leukemia provides mechanistic insights into adult LIC biologySemantic proximity Read ↗

Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.Semantic proximity Read ↗

GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathwaysSemantic proximity Read ↗

Protein Tyrosine Phosphatase 4A3 (PTP4A3) modulates Src signaling in T-cell Acute Lymphoblastic Leukemia to promote leukemia migration and progressionSemantic proximity Read ↗

Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL.Semantic proximity Read ↗

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.